The exploratory clinical trial sponsored by Tongji Hospital aims to evaluate the safety and efficacy of a novel CAR-T cell therapy targeting CD33, CD123, and CLL-1 in patients with relapsed/refractory myeloid malignancies. Given the high unmet medical need in this patient population, particularly in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), successful outcomes could position this therapy favorably in a competitive landscape dominated by existing treatments such as chemotherapy and other immunotherapies. The trial's design includes a dose escalation followed by a dose expansion phase, which may provide critical insights into the therapy's therapeutic window and potential market entry strategy. The anticipated enrollment of 45 subjects suggests a robust dataset for initial efficacy and safety assessments, which could attract interest from potential partners or investors in the biopharmaceutical sector.